Helix BioMedix (HXBM) Stock Price, News & Analysis

Company Overview

Helix BioMedix, Inc. (OTCMKTS: HXB M) is a clinical-stage biotechnology company focused on the development of novel immunotherapeutic and supportive care products for cancer patients. The company’s research and development efforts center on leveraging the body’s innate immune system to enhance anti-tumor responses, with a pipeline that includes biologics designed to modulate immune checkpoints and activate phagocytic cells against tumor targets.

Operating from its headquarters in Cambridge, Massachusetts, Helix BioMedix applies proprietary discovery and screening platforms to identify and optimize lead candidates. The company’s preclinical and early-stage clinical programs are supported by partnerships with academic institutions and government research agencies, which aim to validate product mechanisms, assess safety and efficacy, and advance regulatory filings.

Founded to address the critical need for innovative cancer therapies, Helix BioMedix continues to build its internal capabilities in immunology, translational medicine and biomanufacturing. By collaborating with external experts and leveraging grant funding, the company seeks to accelerate development timelines and position its candidates for future trials in solid tumors and hematologic malignancies.

Key Stats

• Today's Range: $3.50 to $3.90
• 50-Day Range: $3.50 to $5.68
• 52-Week Range: $3.50 to $6.45
• Volume: 439 shs
• Average Volume: 24 shs
• Market Capitalization: $770 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

HXBM Stock Analysis - Frequently Asked Questions

How have HXBM shares performed this year?

Helix BioMedix's stock was trading at $8.00 at the beginning of 2025. Since then, HXBM shares have decreased by 56.3% and is now trading at $3.50.

How do I buy shares of Helix BioMedix?

Shares of HXBM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Today: 9/25/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:HXBM
• CIK: N/A
• Web: www.helixbiomedix.com
• Phone: (425) 402-8400
• Fax: 425-806-2999
• Employees: 8
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 220,000
• Free Float: 204,000
• Market Cap: $770 thousand
• Optionable: Not Optionable
• Beta: 0.50